Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model

Vaccine

Volumn 24, Issue 18, 2006, Pages 3727-3734

  Barry, Eileen M ^a   Wang, Jin ^a   Wu, Tao ^a   Davis, Tamar ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

ETEC vaccine; Live vector; Shigella vaccine

Indexed keywords

ATTENUATED LIVE SHIGELLA-ENTEROTOXIGENIC ESCHERICHIA COLI VACCINE; BACTERIAL ANTIGEN; BACTERIAL VACCINE; CVD 1208; CVD 1233; CVD 1252; ENTEROTOXIGENIC ESCHERICHIA COLI VACCINE; ENTEROTOXIN; SHIGELLA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CONTROLLED STUDY; ENTEROTOXIGENIC ESCHERICHIA COLI; EXPERIMENTAL INFECTION; GENE DELETION; GENE VECTOR; GUINEA PIG; IMMUNE RESPONSE; IMMUNOGENICITY; KERATOCONJUNCTIVITIS; NONHUMAN; PRIORITY JOURNAL; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FIMBRIAE PROTEINS; GENE DELETION; GUINEA PIGS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KERATOCONJUNCTIVITIS; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 33646146463     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.013     Document Type: Article

References (30)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77 8 (1999) 651-666
2. Black R.E., Merson M.H., Huq I., Alim A.R., and Yunus M. Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development. Lancet 1 8212 (1981) 141-143
3. Hyams K.C., Bourgeois A.L., Merrell B.R., Rozmajzl P., Escamilla J., Thornton S.A., et al. Diarrheal disease during Operation Desert Shield. N Engl J Med 325 20 (1991) 1423-1428
4. Wolf M.K., Taylor D.N., Boedeker E.C., Hyams K.C., Maneva D.R., Levine M.M., et al. Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops deployed to the Middle East. J Clin Microbiol 31 4 (1993) 851-856
5. Haberberger Jr. R.L., Mikhail I.A., Burans J.P., Hyams K.C., Glenn J.C., Diniega B.M., et al. Travelers' diarrhea among United States military personnel during joint American-Egyptian armed forces exercises in Cairo. Egypt Mil Med 156 1 (1991) 27-30
6. Svennerholm A.M., and Steele D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol 18 2 (2004) 421-445
7. Talukder K.A., Islam M.A., Khajanchi B.K., Dutta D.K., Islam Z., Safa A., et al. Temporal shifts in the dominance of serotypes of Shigella dysenteriae from 1999 to 2002 in Dhaka, Bangladesh. J Clin Microbiol 41 11 (2003) 5053-5058
8. Gangarosa E.J., Perera D.R., and Mata L.J. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J Infect Dis 122 (1970) 170-180 (GENERIC)
9. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., and Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Organ 45 4 (1971) 457-464
10. Mel D.M., Terzin A.L., and Vuksic L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ 32 5 (1965) 647-655
11. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 7 (1999) 3437-3443
12. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., and Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 67 2 (1999) 782-788
13. Black R.E. Pathogens that cause travelers' diarrhea in Latin America and Africa. Rev Infect Dis 8 Suppl. 2 (1986) S131-S135
14. Levine M.M., Nalin D.R., Hoover D.L., Bergquist E.J., Hornick R.B., and Young C.R. Immunity to enterotoxigenic Escherichia coli. Infect Immun 23 3 (1979) 729-736
15. Levine M.M., Giron J.A., and Noriega F. Fimbrial vaccines (1994), CRC Press
16. Steinsland H., Valentiner-Branth P., Perch M., Dias F., Fischer T.K., Aaby P., et al. Enterotoxigenic Escherichia coli infections and diarrhea in a cohort of young children in Guinea-Bissau. J Infect Dis 186 12 (2002) 1740-1747
17. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila L., Oksanen P., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338 8778 (1991) 1285-1289
18. Formal S.B., Dammin G.J., LaBrec E.H., and Schneider H. Experimental Shigella infections: characteristics of a fatal infection produced in guinea pigs. J Bacteriol 75 (1958) 604-610 (GENERIC)
19. Formal S.B., Kent T.H., May H.C., Palmer A., Falkow S., and LaBrec E.H. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol 92 1 (1966) 17-22
20. Levine M.M., DuPont H.L., and Formal S.B. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis 127 3 (1973) 261-270
21. Noriega F.R., Losonsky G., Lauderbaugh C., Liao F.M., Wang J.Y., and Levine M.M. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun 64 8 (1996) 3055-3061
22. Noriega F.R., Wang J.Y., Losonsky G., Maneval D.R., Hone D.M., and Levine M.M. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun 62 11 (1994) 5168-5172
23. Altboum Z., Levine M.M., Galen J.E., and Barry E.M. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain. Infect Immun 71 3 (2003) 1352-1360
24. Galen J.E., Nair J., Wang J.Y., Wasserman S.S., Tanner M.K., Sztein M.B., et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 67 12 (1999) 6424-6433
25. Koprowski H., Levine M.M., Anderson R.J., Losonsky G., Pizza M., and Barry E.M. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect Immun 68 9 (2000) 4884-4892
26. Altboum Z., Barry E.M., Losonsky G., Galen J.E., and Levine M.M. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect Immun 69 5 (2001) 3150-3158
27. Koprowski H., Levine M.M., Anderson R.J., Losonsky G., Pizza M., and Barry E.M. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect Immun 68 9 (2000) 4884-4892
28. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a Bearing Guanine Auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190 10 (2004) 1745-1754
29. Pizza M., Fontana M.R., Giuliani M.M., Domenighini M., Magagnoli C., Giannelli V., et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med 180 6 (1994) 2147-2153
30. Barry EM, Altboum Z, Losonsky G, Levine M.M. Immune responses elicited against multiple fimbriae and mutant LT from enterotoxigenic E. coli expressed in attenuated Shigella vaccine strains. Vaccine 21, 333-340.